SLC5A2 and cardiac hypertrophy: SGLT2 inhibitors were originally developed as a hypoglycemic agent that inhibits renal tubular reabsorption of glucose to lower blood glucose by increasing glycosuria, an insulin-independent mechanism that appears to provide durable hypoglycemic efficacy at any stage of the natural course of T2DM [25], thereby reducing pathological myocardial hypertrophy.